Todd Vanderah of the University of Arizona had been seeking ways to create alternative analgesics. He and his colleagues are now seeing promise in a specific class of chemical compounds that may help people find pain relief brought about by metastatic breast cancer.

Those compounds, said Vanderah, head of the Department of Pharmacology in the College of Medicine – Tucson, are unique, non-psychotropic cannabinoids. In other words, they do not bring about the euphoria typically associated with cannabinoids. What's more, these particular chemical compounds help slow bone loss, unlike opioids, while slowing the proliferation of the cancer.

Vanderah and his colleagues have published several peer-reviewed studies investigating unique cannabinoids' analgesic viability as well as the mechanisms behind opioids' addictive properties.

The latest studies show that sustained opioid use in metastatic cancer may enhance bone loss, said Vanderah, an expert on opioid addiction, whereas non-psychotropic cannabinoids actually inhibit bone loss and pain.

A recent publication by Vanderah and his colleagues in the journal Neuropharmacology demonstrated that the combination of the non-psychotropic cannabinoid with a low dose of an opioid resulted in pain relief while significantly reducing the addictive property of the opioid.

Researchers are now using different kinds of cannabinoids to slow the proliferation and spread of cancer. Vanderah said there are 400 chemical compounds within a marijuana plant, with only one or two being tested for medicinal use. Studies so far have shown that cannabinoids slow the spread of brain and colon cancer in addition to breast cancer.

"It won't kill the cancer cells off, but it slows the proliferation," he said, adding that this finding was something of a delightful surprise. "Now we're trying to figure out how the cannabinoid slows the breast cancer proliferation."